Medscape5d
A Strategy for Combating Melanoma With Oncogenic c-Myc Inhibitors and Targeted Nanotherapy
We developed a novel strategy for delivering oncogenic c-Myc inhibitors for targeting melanoma cells. c-Myc prodrugs (PDs) were developed based on Sn-2 phospholipid PDs by coupling 10058-F4 ...
BioWorld19d
Chinese scientists describe new WDR5/c-Myc interaction inhibitors
Researchers at Children’s Hospital of Fudan University, Shanghaitech University and Suzhou Zhongke New Drug Incubator Biomedical Technology Co. Ltd. have identified WD repeat-containing protein 5 ...
Nature13y
Molecular basis for the actions of Hsp90 inhibitors and cancer therapy
Heat-shock protein 90 (Hsp90) inhibitor downregulates c-Myc expression and upregulates the expression of tumor repressor proteins such as p53 and pRB, inhibiting the G1/S transition and causing G2 ...
BioWorld26d
USP7 inhibitor exerts robust antitumor activity in lung cancer models
Ubiquitin-specific protease 7 (USP7) is involved in DNA repair and cell cycle progression and, due to its control over the ubiquitination of key proteins, may impact oncogenes like MDM2 and c-Myc, as ...
Baylor College of Medicine4y
Project 3: Targeting Endoplasmic Reticulum Stress Sensor IRE1 to Enhance Chemotherapy Sensitivity in MYC-driven Breast Cancer
Activation of MYC is synthetic lethal with IRE1/XBP1 pathway inhibition. We found that inhibition of the IRE1/XBP1 pathway with a highly selective IRE1 RNase inhibitor ORIN1001 suppresses ...
Medscape18d
A Strategy for Combating Melanoma With Oncogenic c-Myc Inhibitors and Targeted Nanotherapy
The objectives of the present work were: to develop and characterize an Sn-2 lipase-labile PD of a c-Myc inhibitor; to demonstrate the stability of the c-Myc-PD in the PFC NPs; to demonstrate the ...